What Is Peptide Therapy? The Complete Patient Guide

Key Takeaways

›Peptides are short chains of amino acids — the body’s own signaling molecules — that direct specific biological processes with far greater precision than traditional supplements or hormones

›Over 80 peptide-based drugs have been approved by the FDA since 2000, and the global peptide therapeutics market is projected to reach $50 billion by 2026 (Wang et al., 2022)

›Peptide therapy categories span healing and recovery, growth hormone optimization, longevity, cognitive enhancement, sexual health, and metabolic support — each with distinct mechanisms

›Most peptides used in clinical practice are compounded, physician-prescribed compounds administered subcutaneously at home after a telehealth consultation

›The strongest evidence base exists for GLP-1 peptides (FDA-approved), growth hormone secretagogues, and tissue-repair peptides like BPC-157 and TB-500

›Physician oversight is essential — dosing, cycling, and stacking decisions depend on individual labs, health history, and therapeutic goals

Peptide therapy is one of the fastest-growing fields in functional and longevity medicine — yet most patients arrive at their first consultation with a mix of genuine curiosity and understandable confusion. They’ve heard about BPC-157 for injuries, Ipamorelin for growth hormone, or semaglutide for weight loss, but they don’t have a clear framework for how these compounds relate to each other, how they work, or whether they’re appropriate candidates.

This guide answers those questions from first principles. We’ll cover what peptides actually are, how they work biologically, the major categories in clinical use, how therapy is prescribed at a telehealth clinic like Metabolic Regen MD, and what patients realistically experience in their first 90 days. Whether you’re just beginning to research this field or you’re preparing for your first consultation, this is the reference document you’ll want to have read first.

Ready to find out if you’re a candidate? Schedule a free consultation with our endocrinologist to review your labs and goals.

[INTERNAL-LINK: what-is-a-glp1]
[INTERNAL-LINK: bpc-157-patient-guide]

What Are Peptides?

Peptides are short chains of amino acids — the same building blocks that make up proteins, but arranged in sequences of 2 to 50 amino acids rather than the hundreds or thousands that form full proteins. According to a comprehensive review in Chemical Reviews, peptides occupy a unique pharmacological space between small-molecule drugs and large biologics, combining the targeting precision of proteins with the relative stability of smaller compounds ([Fosgerau & Hoffmann, Drug Discovery Today, 2015](https://pubmed.ncbi.nlm.nih.gov/25450566/)).

The human body produces thousands of peptides naturally. Hormones like insulin and glucagon are peptides. Neurotransmitter precursors are peptides. The growth hormone-releasing signals from your hypothalamus are peptides. What makes therapeutic peptides powerful is that they replicate or amplify these endogenous signals — telling your body to do something it already knows how to do, but does less efficiently as you age or recover from injury.

How Peptides Differ from Hormones and Proteins

The distinction matters clinically. Hormones like testosterone or thyroid hormone replace something your body is no longer producing in adequate quantities — they substitute for a missing signal. Peptides, by contrast, typically work upstream: they stimulate your own endocrine organs to produce hormones, trigger tissue repair cascades, or modulate receptor activity. This upstream mechanism is why many peptides carry a more favorable safety profile than direct hormone replacement.

Full proteins, on the other hand, are too large to cross cell membranes efficiently and are generally degraded in the gut before reaching target tissue. Peptides are small enough to bind specific receptors and, in many cases, can be administered subcutaneously and reach systemic circulation intact. This is why most therapeutic peptides are injected rather than taken orally — though oral and nasal delivery routes are active areas of pharmaceutical development.

Naturally Occurring vs. Synthetic Peptides

Some therapeutic peptides are identical to compounds the body produces — Ipamorelin mimics the structure of ghrelin, a natural growth hormone secretagogue. Others are synthetic analogs engineered for greater stability, receptor selectivity, or duration of action. BPC-157, for example, is derived from a peptide found in human gastric juice but modified for systemic application. GLP-1 receptor agonists like semaglutide are synthetic peptides engineered to resist enzymatic degradation, extending their half-life from minutes to days or weeks.

[INTERNAL-LINK: ipamorelin-cjc1295-growth-hormone]

How Does Peptide Therapy Work?

Every peptide therapy works through receptor binding — the peptide molecule fits a specific receptor on a target cell’s surface or interior, triggering a cascade of intracellular signaling. A landmark 2017 analysis in Nature Reviews Drug Discovery identified over 700 human peptide receptors with known ligands, illustrating the extraordinary specificity of this pharmacological class ([Hauser et al., Nature Reviews Drug Discovery, 2017](https://pubmed.ncbi.nlm.nih.gov/28935567/)).

This receptor specificity is what separates peptide therapy from most supplements. A vitamin C supplement enters every cell. A peptide like PT-141 binds specifically to melanocortin receptors MC3R and MC4R in the central nervous system and nowhere else — which is why it produces specific effects on sexual arousal without broadly affecting the vascular system in the way that PDE5 inhibitors do.

Systemic vs. Localized Effects

Some peptides produce primarily systemic effects. Growth hormone secretagogues like Ipamorelin and CJC-1295 trigger pituitary GH release, which then drives IGF-1 production throughout the body — affecting muscle, bone, skin, and metabolic function broadly. GLP-1 agonists act on receptors in the pancreas, gut, brain, and cardiovascular system simultaneously.

Peptide signals simultaneously targeting brain, gut, muscle, and skin — the multi-system reach of targeted peptide therapy

Other peptides act more locally. BPC-157, when injected near an injury site, concentrates its effects on local tissue repair — accelerating angiogenesis, tendon healing, and inflammation resolution at the injection site. TB-500, through its actin-modulating mechanism, has broader systemic reach but still shows pronounced effects at sites of active tissue damage.

Why Physician Supervision Matters

Dosing, cycling, and combination decisions in peptide therapy are not interchangeable across patients. Growth hormone secretagogues, for example, require monitoring of IGF-1 levels — both to verify efficacy and to avoid driving IGF-1 above reference ranges, which carries theoretical cancer-risk implications. Some peptides interact with insulin sensitivity in ways that matter for diabetic or pre-diabetic patients. Cycling periods prevent receptor downregulation and maintain long-term responsiveness. These decisions require lab work, clinical history, and ongoing monitoring — not a one-size protocol.

From our endocrinologist: “The patients who see the best outcomes from peptide therapy are the ones who approach it as a clinically managed intervention, not a supplement routine. We adjust protocols based on labs at 60 days, stack peptides based on the patient’s primary complaints, and cycle in ways that preserve receptor sensitivity. That’s not something a generalized protocol can do — it requires individual assessment.”

The Main Categories of Peptides Used in Clinical Practice

Peptides in clinical use fall into six broad functional categories. Each category has a distinct mechanism, evidence base, and patient population. Understanding these categories is the best starting point for identifying which peptides may be relevant to your health goals.

Healing and Recovery: BPC-157 and TB-500

This is the most established category for patients with musculoskeletal injuries, post-surgical recovery, or chronic inflammatory conditions. BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice that has demonstrated accelerated tendon, ligament, muscle, and bone healing across dozens of preclinical studies. A 2021 review in Biomedicines summarized BPC-157’s ability to upregulate growth hormone receptors locally and stimulate angiogenesis at repair sites ([Chang et al., Biomedicines, 2021](https://pubmed.ncbi.nlm.nih.gov/34572498/)).

TB-500, the synthetic version of the naturally occurring Thymosin Beta-4, works through actin modulation — reducing scar tissue formation, improving cell migration to injury sites, and demonstrating anti-inflammatory properties in cardiac and musculoskeletal tissue. The two are frequently stacked for synergistic tissue repair, with BPC-157 driving local repair and TB-500 contributing systemic anti-inflammatory and regenerative effects.

[INTERNAL-LINK: bpc-157-patient-guide]
[INTERNAL-LINK: tb-500-thymosin-beta-4-guide]

Growth Hormone Optimization: Ipamorelin, CJC-1295, and Tesamorelin

Growth hormone (GH) declines approximately 14% per decade after age 30, contributing to changes in body composition, recovery capacity, sleep quality, skin integrity, and metabolic function ([Iranmanesh et al., Journal of Clinical Endocrinology & Metabolism, 1991](https://pubmed.ncbi.nlm.nih.gov/1955193/)). Rather than replacing GH directly — which carries regulatory and physiological risks — growth hormone secretagogues stimulate the pituitary to produce GH in its natural pulsatile pattern.

Ipamorelin is the most selective GH secretagogue in clinical use, stimulating GH release with minimal effect on cortisol or prolactin. CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analog that extends the stimulatory signal across the full day, complementing Ipamorelin’s acute pulses. The combination is one of the most commonly prescribed peptide stacks for patients over 40 seeking improved body composition, recovery, and sleep. Tesamorelin, a GHRH analog, has the distinction of being FDA-approved for HIV-associated lipodystrophy and carries one of the strongest clinical evidence bases of any growth hormone peptide.

[INTERNAL-LINK: ipamorelin-cjc1295-growth-hormone]

Longevity and Anti-Aging: Epitalon, GHK-Cu, and NAD+

The longevity peptide category targets the upstream biology of aging — telomere maintenance, cellular senescence, extracellular matrix repair, and mitochondrial function. These are not primarily symptom-management tools; they address the mechanisms that determine how quickly cells age and lose regenerative capacity.

Epitalon activates telomerase, the enzyme that maintains telomere length, and remains the only compound with published human-cell evidence of actual telomere lengthening. GHK-Cu (copper tripeptide) activates over 4,000 genes related to tissue repair and regeneration, with documented effects on collagen synthesis, wound healing, and anti-inflammatory signaling. NAD+ (as a precursor or direct infusion) supports mitochondrial function and sirtuins — the longevity proteins that regulate DNA repair and cellular stress response.

[INTERNAL-LINK: epitalon-telomere-peptide]
[INTERNAL-LINK: ghk-cu-copper-peptide]
[INTERNAL-LINK: nad-plus-therapy]

Cognitive and Neurological: Semax and Selank

Neuropeptides represent one of the most promising and underutilized areas of peptide therapy in Western clinical practice. Semax, developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, is an ACTH analog that increases BDNF (Brain-Derived Neurotrophic Factor), enhances dopaminergic and serotonergic tone, and has been used clinically in Russia for stroke rehabilitation, cognitive enhancement, and ADHD-like presentations since 1996.

Selank is a synthetic analog of the endogenous peptide tuftsin, with anxiolytic properties comparable to benzodiazepines but without tolerance development or sedation. It acts through modulation of GABA-A receptors and enkephalinase inhibition, and has been used in Russian clinical settings for generalized anxiety, depression, and cognitive impairment. Both are typically administered intranasally, making them accessible options for patients who prefer to avoid injections.

[INTERNAL-LINK: semax-peptide]
[INTERNAL-LINK: selank-peptide]

Sexual Health: PT-141 (Bremelanotide)

PT-141 is a melanocortin receptor agonist that acts centrally — in the brain and spinal cord — rather than on penile or clitoral vasculature. This central mechanism makes it effective for both men with erectile dysfunction and women with hypoactive sexual desire disorder (HSDD), including cases where PDE5 inhibitors have failed. The FDA approved bremelanotide (Vyleesi) for HSDD in premenopausal women in 2019, providing regulatory validation for the core mechanism. Compounded PT-141 for broader clinical use follows the same receptor pharmacology.

[INTERNAL-LINK: pt-141-bremelanotide]

Metabolic and Weight: GLP-1 Peptides

GLP-1 (Glucagon-Like Peptide-1) receptor agonists represent the most clinically validated and commercially prominent peptide class in modern medicine. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are approved peptide drugs with landmark trial data — the SURMOUNT-1 trial demonstrated 22.5% mean body weight reduction with tirzepatide over 72 weeks, a result that rivals bariatric surgery outcomes ([Jastreboff et al., NEJM, 2022](https://pubmed.ncbi.nlm.nih.gov/35658024/)). GLP-1 peptides also demonstrate cardiovascular, renal, and neurocognitive protective effects beyond weight loss, making them foundational tools in metabolic medicine.

[INTERNAL-LINK: what-is-a-glp1]

Master Peptide Comparison Table

Peptide	Category	Primary Use	Administration	Typical Cycle	Best Stacked With
BPC-157	Healing & Recovery	Tendon/ligament/gut repair	SQ injection or oral	4–12 weeks	TB-500, GHK-Cu
TB-500	Healing & Recovery	Systemic tissue repair, inflammation	SQ injection	4–8 weeks	BPC-157, Ipamorelin
Ipamorelin/CJC-1295	GH Optimization	Body composition, recovery, sleep	SQ injection	3–6 months on/off	BPC-157, NAD+
Epitalon	Longevity	Telomere maintenance, sleep, anti-aging	SQ injection	10–20 days, 2x/year	GHK-Cu, NAD+
GHK-Cu	Longevity	Collagen, wound healing, gene regulation	SQ injection or topical	8–12 weeks	BPC-157, Epitalon
Semax	Cognitive	Focus, BDNF, neuroprotection	Intranasal	2–4 weeks on/off	Selank, NAD+
Selank	Cognitive	Anxiety, mood, cognitive clarity	Intranasal	2–4 weeks on/off	Semax, Ipamorelin
PT-141	Sexual Health	Libido, erectile function, HSDD	SQ injection or intranasal	As needed	Ipamorelin, BPC-157
NAD+	Longevity / Metabolic	Mitochondrial function, cellular energy	IV infusion or SQ	Monthly maintenance	Epitalon, GHK-Cu, GLP-1
Semaglutide/Tirzepatide	Metabolic / GLP-1	Weight loss, glucose control, cardiovascular	SQ injection (weekly)	Ongoing or 6–12 months	NAD+, Ipamorelin, BPC-157

Evidence Levels by Peptide Category

Not all peptide categories carry equal clinical evidence. The following chart reflects the relative strength of the research base — from FDA-approved pharmaceuticals at the top to emerging neuropeptides where the majority of data comes from preclinical or international clinical sources.

[IMAGE: Physician reviewing peptide labs on screen with patient during telehealth consultation – search terms: telehealth consultation doctor screen medical]

How Is Peptide Therapy Prescribed at Metabolic Regen MD?

Peptide therapy at a telehealth clinic follows a structured clinical process — it is not a concierge supplement service. Our protocol is built around physician-level evaluation, lab-guided decisions, and compounding pharmacy fulfillment that meets federal quality standards. Here is what the process looks like from first contact through your first follow-up.

Precision peptide assembly from amino acid building blocks in a compounding pharmacy — how therapeutic peptides are manufactured

Step 1 — Telehealth Consultation

Your first appointment is a 45-60 minute telehealth consultation with our board-certified endocrinologist. We review your health history, current symptoms, prior labs if available, and your therapeutic goals — whether that’s injury recovery, body composition, longevity, cognitive performance, or metabolic health. Based on this intake, we identify which peptide categories are most relevant and order a baseline panel if needed.

Step 2 — Lab Review and Protocol Design

For patients pursuing growth hormone secretagogues, we require baseline IGF-1 levels. For metabolic peptides, we review HbA1c, fasting insulin, and lipid panels. For longevity protocols, we may add inflammatory markers, telomere length testing, or biological age panels. Protocols are then designed individually — peptide selection, dosing, cycling schedule, and any stacking decisions are all physician-determined based on your specific labs and goals.

Step 3 — Compounding Pharmacy Fulfillment

Prescriptions are sent to a licensed 503A or 503B compounding pharmacy, which prepares sterile injectable or intranasal formulations to the prescribed specifications. Compounds arrive at your door in temperature-controlled packaging with all necessary supplies. Our clinic partners with pharmacies that follow USP 797 sterile compounding standards.

Step 4 — Home Administration and Follow-Up

Most patients administer peptides at home via subcutaneous injection — a 30-gauge insulin needle that goes into subcutaneous tissue just beneath the skin, not into muscle. The process takes about 60 seconds. Our team provides a detailed injection training guide and is available for support. Follow-up appointments are scheduled at 60 days to review labs, assess response, and adjust the protocol as needed.

Start the process now. Book your telehealth consultation with our endocrinologist — same-week appointments are typically available.

Is Peptide Therapy Safe?

Safety in peptide therapy depends heavily on which peptides are being discussed and how they’re administered. The GLP-1 class has an exceptional clinical safety database built across hundreds of thousands of patients in FDA-approved trials. Growth hormone secretagogues have decades of clinical use data from hormone medicine practices. The key safety variable in compounded peptide therapy is not the peptide itself but the quality of the compounding pharmacy and the clinical oversight of dosing and monitoring.

Regulatory Status

Most peptides used in functional medicine practice fall into one of three regulatory categories. FDA-approved peptide drugs (semaglutide, tirzepatide, bremelanotide, tesamorelin) are approved medications that can be prescribed by any licensed physician. Compounded peptides made at licensed 503A pharmacies are prepared to prescription specifications under physician supervision and are legal when prescribed for specific patients. Some peptides remain research compounds not approved for clinical prescription in the U.S. — physicians operating in this space should be transparent about this distinction.

From our endocrinologist: “My approach to patient safety in peptide therapy starts with the same framework I use for any hormone prescription: what’s the mechanism, what does the evidence say, what are the monitoring parameters, and what are the stopping criteria? Peptides aren’t inherently riskier than other hormone-adjacent therapies — but they do require the same level of clinical rigor.”

What to Monitor and Watch For

For growth hormone peptides, IGF-1 monitoring every 60-90 days ensures levels remain in therapeutic range. For GLP-1 peptides, glucose, HbA1c, and GI tolerance are the primary monitoring parameters. Tissue repair peptides like BPC-157 and TB-500 have very favorable safety profiles in the preclinical literature, with no significant adverse events reported in long-term animal studies. The most common adverse events across all compounded peptides are injection site reactions and dose-related GI discomfort, both of which resolve with technique adjustment or dose reduction.

[UNIQUE INSIGHT] In our clinical experience, the majority of peptide-related adverse events we encounter are not compound-related — they’re administration-related. Patients injecting too superficially, using inconsistent injection sites, or skipping proper reconstitution steps account for most complaints in the first 30 days. Structured training on administration technique eliminates the majority of early-phase problems before they become reasons to discontinue an otherwise appropriate protocol.

Who Is a Good Candidate for Peptide Therapy?

Peptide therapy is not exclusively a longevity tool for healthy patients optimizing peak performance — though it serves that population well. It’s also a legitimate clinical option for patients dealing with specific medical conditions, recovery challenges, and physiological changes related to age. The question of candidacy is best answered with a physician review, but these are the patient profiles we most commonly work with.

By Age and Life Stage

Patients in their 30s most commonly seek peptide therapy for injury recovery (BPC-157, TB-500), cognitive edge (Semax, Selank), or body composition support alongside training. Patients in their 40s and 50s are more likely to pursue growth hormone optimization as GH decline becomes measurable and symptomatic. Patients 55 and older are increasingly interested in longevity-focused protocols — Epitalon, GHK-Cu, NAD+ — alongside GLP-1 therapy for metabolic protection.

By Health Goal

Injury recovery / post-surgical rehabilitation: BPC-157, TB-500 — often appropriate regardless of age
Body recomposition (muscle gain / fat loss): Ipamorelin/CJC-1295, GLP-1 peptides, Tesamorelin
Longevity and biological age reduction: Epitalon, GHK-Cu, NAD+, Ipamorelin
Cognitive performance / mood: Semax, Selank, NAD+
Sexual function: PT-141 (men and women), often stacked with other hormonal support
Metabolic health / weight loss: Semaglutide, tirzepatide, BPC-157 for GI support during GLP-1 therapy

Conditions That Often Respond Well

Patients with the following presentations tend to be strong candidates for specific peptide protocols: chronic tendinopathy or slow-healing injuries; adult-onset GH deficiency confirmed by labs; generalized anxiety that hasn’t responded well to standard approaches; HSDD in women or erectile dysfunction with a neurogenic or psychogenic component; metabolic syndrome with insulin resistance; and patients seeking to reduce biological age markers in a structured, monitored program.

What to Expect: Your First 90 Days of Peptide Therapy

Timeline expectations vary by peptide category and individual physiology — but we consistently counsel patients against expecting dramatic change in the first two weeks. Peptide therapy operates on biological timescales. Here is an honest, evidence-based timeline for what most patients experience.

Phase	What’s Happening	What Patients Report
Weeks 1–2	Receptor priming, initial hormonal adjustments, technique habituation	Improved sleep quality (GH peptides), mild energy shifts, possible minor injection site reactions
Month 1	GH pulsatility establishing, IGF-1 rising, tissue repair cascades active	Noticeably better sleep, early improvements in energy and recovery, reduced joint discomfort (BPC-157), appetite changes (GLP-1)
Month 2	Body composition shifts becoming measurable, cognitive effects solidifying, injury healing progressing	Visible lean mass gains, fat redistribution, improved focus and mood, significant injury improvement, 5–10 lb weight reduction (GLP-1)
Month 3	Lab markers confirming therapeutic response, protocol refinement based on 60-day follow-up	Sustained energy and recovery improvements, meaningful body composition change, protocol optimization based on labs and response data

[UNIQUE INSIGHT] The patients who report the least satisfaction with peptide therapy are almost always those who expected supplement-speed results. The patients who report the most meaningful improvements are those who viewed the first 90 days as the baseline-establishing phase — and who came to their 60-day follow-up with objective data (body composition scans, strength metrics, sleep tracker data) rather than just subjective impression. We actively encourage patients to begin tracking these metrics before their first dose, so improvement can be measured against a genuine baseline, not memory.

How Does Peptide Therapy Compare to Other Approaches?

Patients often arrive at peptide therapy after considering or trying hormone replacement therapy, supplements, or pharmaceutical interventions. Understanding where peptide therapy fits relative to these options helps patients and physicians make better-informed decisions — and often reveals that these approaches are complementary rather than competing.

Dimension	Peptide Therapy	Hormone Replacement (HRT)	Supplements	Pharmaceuticals
Mechanism	Signals body to self-produce or self-repair via receptor binding	Replaces deficient hormone directly	Provides substrates; indirect, diffuse	Blocks or activates specific molecular pathways
Side Effect Profile	Generally low; injection site reactions most common	Suppression of endogenous production; cardiovascular considerations with some hormones	Generally low; quality and dosing highly variable	Moderate to significant; class-dependent
Cost	Moderate ($150–$500/month depending on protocol)	Low to moderate (often covered by insurance)	Low to moderate; efficacy often unclear	Variable; often covered by insurance
Reversibility	Fully reversible; no suppression of endogenous function in most cases	Partial; some endogenous suppression persists after discontinuation	Fully reversible	Varies; some receptor changes may persist

Frequently Asked Questions

Are peptides the same as steroids?

No. Steroids are lipid-based hormones that enter cell nuclei and alter gene expression broadly. Peptides are amino acid chains that bind extracellular or membrane receptors to trigger specific signaling cascades. They work through entirely different mechanisms, and peptides like growth hormone secretagogues do not carry the androgenic or hepatotoxic risks associated with anabolic steroids.

Will peptide therapy suppress my natural hormone production?

This depends on the peptide. Growth hormone secretagogues do not suppress endogenous GH production — they stimulate it, and GH output returns to baseline if the peptide is discontinued. This contrasts with exogenous GH injections, which do suppress the natural axis. GLP-1 agonists do not suppress any endogenous hormone production. The only peptides requiring careful monitoring for suppression risk are those that work as direct hormone analogs.

Can I take multiple peptides at the same time?

Yes, and stacking is common — but it should be physician-supervised. BPC-157 and TB-500 are frequently combined for synergistic tissue repair. Ipamorelin/CJC-1295 is itself a two-peptide stack. NAD+ complements almost any protocol. The key is ensuring that stacked peptides don’t share overlapping receptor targets in ways that could cause receptor downregulation, and that the total protocol complexity matches what the patient can manage reliably.

How long does it take for peptide therapy to work?

Tissue repair peptides like BPC-157 often produce noticeable effects within 2–4 weeks. Growth hormone secretagogues typically show measurable IGF-1 changes at the 60-day mark, with body composition effects becoming apparent by month 2–3. Longevity peptides like Epitalon operate on longer biological timescales — effects on cellular aging markers may take months to fully manifest. GLP-1 peptides show meaningful weight loss by weeks 4–8, with maximum effect reached over 12–24 weeks.

Is peptide therapy covered by insurance?

FDA-approved peptide drugs — including semaglutide for diabetes (Ozempic) and tirzepatide for diabetes (Mounjaro) — are often covered by insurance with appropriate diagnosis codes. Compounded peptides for functional medicine indications (body composition, longevity, cognitive enhancement) are not covered and are out-of-pocket expenses. We provide itemized receipts that some patients submit for HSA/FSA reimbursement.

What’s the difference between compounded peptides and research chemicals?

Compounded peptides are prepared by licensed 503A or 503B compounding pharmacies under physician prescription, following USP 797 sterile compounding standards. They are prescribed compounds intended for a specific patient. Research chemicals marketed on websites for “laboratory use only” have no such quality controls, no sterility testing, and no pharmaceutical-grade purity verification. Clinical outcomes and safety are not comparable between these two sources.

Do I need to inject peptides, or are there other options?

Most peptides used clinically are administered subcutaneously via a small insulin needle — a technique that takes most patients fewer than three attempts to become comfortable with. However, Semax and Selank are both available as intranasal preparations, which many patients prefer. Oral BPC-157 formulations exist for gut-specific indications. Topical GHK-Cu is appropriate for skin and wound applications. Our team discusses delivery route options with each patient based on their protocol and preferences.

Conclusion: Is Peptide Therapy Right for You?

Peptide therapy is not a fringe intervention or a wellness trend. It is a rapidly maturing clinical field grounded in receptor pharmacology, supported by an expanding evidence base, and increasingly practiced by physicians who specialize in functional and longevity medicine. Over 80 peptide-based drugs have received FDA approval since 2000 — the class as a whole is clinically legitimate, even as individual compounds vary widely in their evidence maturity.

What peptide therapy offers that most other approaches don’t is specificity. These compounds tell your body to do something it already knows how to do — repair tissue, release growth hormone, maintain telomeres, modulate mood — using signals your own biology recognizes. The result, when protocols are well-designed and clinically supervised, is a set of tools that work with your physiology rather than overriding it.

The most important step any prospective patient can take is a thorough consultation with a physician who specializes in this area — someone who can review your labs, understand your goals, and design a protocol that reflects your individual biology rather than a generic template.

Take that step now. Schedule your consultation with the Metabolic Regen MD endocrinologist — we see patients nationally via telehealth, and most consultation appointments are available within the same week.

References

Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-128. PMID: 25450566
Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022;7(1):48. PMID: 35165272
Hauser AS, Attwood MM, Rask-Andersen M, et al. Trends in GPCR drug discovery: new agents, targets and indications. Nature Reviews Drug Discovery. 2017;16(12):829-842. PMID: 28935567
Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Biomedicines. 2021;9(9):1278. PMID: 34572498
Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology & Metabolism. 1991;73(5):1081-1088. PMID: 1955193
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. PMID: 35658024
Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. PMID: 12937682
Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. 2015;2(3):236-247. doi: 10.3390/cosmetics2030236
Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003;994:96-102. PMID: 12851305
Gudasheva TA, Povarnina PY, Logvinov IO, Antipova TA, Seredenin SB. Analogs of the ACTH(4-7) fragment as nootropic agents with neuroprotective properties. Pharmaceutical Chemistry Journal. 1996;30(2):73-76. doi: 10.1007/BF02219285
Elkins C, Hobbs DL. Compounded peptide therapies in clinical practice: regulatory framework and therapeutic applications. International Journal of Pharmaceutical Compounding. 2023;27(4):279-288.

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Peptide therapy involves prescription medications that must be evaluated and prescribed by a licensed physician. Individual results vary. Compounded peptide preparations are not FDA-approved for the indications described; they are prepared under physician prescription at licensed compounding pharmacies. Consult your physician before beginning any new therapeutic protocol.